Accuvest Global Advisors Takes Position in AbbVie Inc. (NYSE:ABBV)

Accuvest Global Advisors bought a new stake in AbbVie Inc. (NYSE:ABBV) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 7,256 shares of the company’s stock, valued at approximately $473,000.

Several other hedge funds have also added to or reduced their stakes in the company. First Command Financial Services Inc. increased its stake in AbbVie by 6.8% in the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock valued at $102,000 after buying an additional 99 shares during the period. Patriot Financial Group Insurance Agency LLC acquired a new stake in AbbVie during the fourth quarter valued at $137,000. Atwood & Palmer Inc. increased its stake in AbbVie by 1,333.3% in the first quarter. Atwood & Palmer Inc. now owns 2,150 shares of the company’s stock valued at $140,000 after buying an additional 2,000 shares during the period. Tradewinds Capital Management LLC increased its stake in AbbVie by 87.2% in the first quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company’s stock valued at $148,000 after buying an additional 1,057 shares during the last quarter. Finally, American National Bank increased its stake in AbbVie by 13.8% in the first quarter. American National Bank now owns 2,471 shares of the company’s stock valued at $161,000 after buying an additional 299 shares during the last quarter. Institutional investors and hedge funds own 67.89% of the company’s stock.

Shares of AbbVie Inc. (NYSE ABBV) traded up 0.31% during midday trading on Friday, hitting $70.66. The stock had a trading volume of 2,971,623 shares. The firm has a 50 day moving average price of $72.13 and a 200 day moving average price of $66.69. The stock has a market cap of $112.64 billion, a PE ratio of 17.38 and a beta of 1.50. AbbVie Inc. has a one year low of $55.06 and a one year high of $75.04.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The business had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. During the same quarter last year, the company earned $1.26 EPS. The business’s quarterly revenue was up 7.6% on a year-over-year basis. On average, equities analysts forecast that AbbVie Inc. will post $5.52 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be given a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a dividend yield of 3.63%. The ex-dividend date is Wednesday, July 12th. AbbVie’s dividend payout ratio (DPR) is presently 62.90%.

ILLEGAL ACTIVITY NOTICE: “Accuvest Global Advisors Takes Position in AbbVie Inc. (NYSE:ABBV)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/08/11/accuvest-global-advisors-buys-new-stake-in-abbvie-inc-nyseabbv-updated.html.

Several analysts recently weighed in on ABBV shares. Vetr upgraded AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 price objective for the company in a report on Monday, May 8th. BMO Capital Markets set a $63.00 price objective on AbbVie and gave the company a “hold” rating in a report on Thursday, April 27th. Credit Suisse Group restated a “hold” rating and issued a $65.00 price objective on shares of AbbVie in a report on Wednesday, June 7th. Zacks Investment Research downgraded AbbVie from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Finally, Deutsche Bank AG lifted their price objective on AbbVie from $64.00 to $65.00 and gave the company a “hold” rating in a report on Friday, April 28th. Nine research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $74.66.

In other news, CFO William J. Chase sold 38,300 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the sale, the chief financial officer now owns 209,043 shares of the company’s stock, valued at approximately $13,660,960.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Rapp bought 4,000 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were acquired at an average cost of $70.45 per share, for a total transaction of $281,800.00. Following the transaction, the director now directly owns 15,498 shares in the company, valued at approximately $1,091,834.10. The disclosure for this purchase can be found here. Insiders have sold a total of 600,026 shares of company stock worth $41,852,724 in the last three months. Corporate insiders own 0.23% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

What are top analysts saying about AbbVie Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AbbVie Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit